LC
BCRX icon

Lindbrook Capital’s BioCryst Pharmaceuticals BCRX Stock Holding History

Lindbrook Capital’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$13.2K Buy
1,757
+154
+10% +$1.24K ﹤0.01% 1537
2024
Q4 		$12.1K Sell
1,603
-468
-23% -$3.55K ﹤0.01% 1553
2024
Q3 		$15.7K Sell
2,071
-747
-27% -$5.68K ﹤0.01% 1423
2024
Q2 		$17.4K Buy
2,818
+2,278
+422% +$12.6K ﹤0.01% 1324
2024
Q1 		$2.74K Sell
540
-144
-21% -$810 ﹤0.01% 2134
2023
Q4 		$4.1K Buy
684
+353
+107% +$2.04K ﹤0.01% 1989
2023
Q3 		$2.34K Sell
331
-686
-67% -$4.93K ﹤0.01% 2067
2023
Q2 		$7.16K Buy
1,017
+752
+284% +$6.04K ﹤0.01% 1641
2023
Q1 		$2.21K Buy
265
+49
+23% +$472 ﹤0.01% 2203
2022
Q4 		$2.48K Buy
216
+76
+54% +$948 ﹤0.01% 2145
2022
Q3 		$2K Sell
140
-78
-36% -$1K ﹤0.01% 1994
2022
Q2 		$2K Sell
218
-8
-4% -$83 ﹤0.01% 1912
2022
Q1 		$4K Buy
+226
New +$3.63K ﹤0.01% 1672
2020
Q2 		– Sell
-248
Closed – – 1724
2020
Q1 		$0 Buy
+248
New +$683 ﹤0.01% 1685

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Lindbrook Capital's BCRX Position: Q1 2025 in Review

Lindbrook Capital increased its BioCryst Pharmaceuticals (BCRX) stake by 9.6% in Q1 2025, buying an estimated $1.24K and bringing the position to 1,757 shares worth $13.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1537.

Lindbrook Capital first reported a position in BCRX in Q1 2020 and has held it in 14 quarters since. The position peaked at $17.4K in Q2 2024. 274 funds tracked by Wall St. Rank hold BCRX as of Q1 2025.

  • Lindbrook Capital held 1,757 shares of BioCryst Pharmaceuticals worth $13.2K as of Q1 2025.
  • Lindbrook Capital bought 154 BioCryst Pharmaceuticals shares in Q1 2025, an estimated $1.24K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #1537 holding.
  • Lindbrook Capital first reported a position in BioCryst Pharmaceuticals in Q1 2020 and has held it in 14 quarters since.
  • Lindbrook Capital's BioCryst Pharmaceuticals position peaked at $17.4K in Q2 2024.
  • 274 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.